Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929794 · ClinicalTrials.gov registry record · Phase 4
Pharmacokinetics of Transdermal Metronidazole
A Phase 4 study of Healthy, sponsored by University of Iowa.
- Active
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05929794: Active Phase 4 study of Healthy, sponsored by University of Iowa.
NCT05929794 is a Phase 4 study of Healthy that is active but no longer recruiting, run by University of Iowa. The registered enrollment target is 24 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05929794, a Phase 4 study of Healthy, is active but no longer recruiting, sponsored by University of Iowa.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a crossover pharmacokinetic clinical study in healthy volunteers to compare metronidazole delivery through skin when a gel or cream metronidazole product is applied to skin treated with a micropatch.
Primary Outcome
Cmax is the highest metronidazole concentration measured in the serum.
Conditions Studied
Interventions
- DRUG Metronidazole 0.75% Topical Gel
- DRUG Metronidazole 0.75% Topical Cream
- DIAGNOSTIC_TEST Transdermal water loss measurement
- DIAGNOSTIC_TEST Electrical Resistance
- DIAGNOSTIC_TEST Skin color measurement
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What the registry record for NCT05929794 still lists
NCT05929794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Metronidazole 0.75% Topical Gel is the first listed.
NCT05929794 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05929794 about?
NCT05929794 is a clinical study titled "Pharmacokinetics of Transdermal Metronidazole". This is a crossover pharmacokinetic clinical study in healthy volunteers to compare metronidazole delivery through skin when a gel or cream metronidazole product is applied to skin treated with a micropatch.
What is the current status of trial NCT05929794?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2024-02-26. Estimated completion is 2026-12.
What conditions does trial NCT05929794 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05929794?
The interventions under investigation include: Metronidazole 0.75% Topical Gel (DRUG), Metronidazole 0.75% Topical Cream (DRUG), Transdermal water loss measurement (DIAGNOSTIC_TEST), Electrical Resistance (DIAGNOSTIC_TEST), Skin color measurement (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05929794?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929794 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05929794's enrollment target sits among peer trials
24 791st of 1090 higher than 254 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
RECRUITING · Phase 4
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
RECRUITING · Phase 4
-
Endothelial Derived Hyperpolarization Factor and Vascular Control
RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
-
VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI